
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2733852/publications.pdf Version: 2024-02-01



LUCAS MODENO

#	Article	IF	CITATIONS
1	Access to earlyâ€phase clinical trials for children with relapsed and refractory neuroblastoma: A multicentre international study. Pediatric Blood and Cancer, 2022, 69, e29551.	1.5	1
2	Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2022, , 1.	2.4	1
3	Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study Journal of Clinical Oncology, 2022, 40, 10039-10039.	1.6	1
4	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with highâ€risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2021, 68, e28794.	1.5	29
5	Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discovery, 2021, 11, 545-559.	9.4	25
6	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2021, 23, 2489-2496.	2.4	3
7	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
8	Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role. Pharmaceuticals, 2021, 14, 810.	3.8	11
9	Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro. Cancers, 2021, 13, 4845.	3.7	0
10	Dickkopf-1 Inhibition Reactivates Wnt/l²-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo. International Journal of Molecular Sciences, 2021, 22, 12921.	4.1	2
11	Methodological advances in the discovery of novel neuroblastoma therapeutics. Expert Opinion on Drug Discovery, 2021, , 1-13.	5.0	5
12	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncology, The, 2021, 22, 1764-1776.	10.7	37
13	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARSâ€CoVâ€2 pandemic. Pediatric Blood and Cancer, 2020, 67, e28557.	1.5	31
14	CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. Cancers, 2020, 12, 1922.	3.7	7
15	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
16	COVIDâ€19 infection in children and adolescents with cancer in Madrid. Pediatric Blood and Cancer, 2020, 67, e28397.	1.5	99
17	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	2.8	13
18	miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma. Cancer Letters, 2020, 477, 49-59.	7.2	24

LUCAS MORENO

#	Article	IF	CITATIONS
19	Noninvasive MRI Native T1 Mapping Detects Response to <i>MYCN</i> -targeted Therapies in the Th- <i>MYCN</i> Model of Neuroblastoma. Cancer Research, 2020, 80, 3424-3435.	0.9	15
20	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
21	Clinical research tools in pediatric oncology: challenges and opportunities. Cancer and Metastasis Reviews, 2020, 39, 149-160.	5.9	9
22	Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial Journal of Clinical Oncology, 2020, 38, 10501-10501.	1.6	4
23	How to address challenges and opportunities in pediatric cancer drug development?. Expert Opinion on Drug Discovery, 2020, 15, 869-872.	5.0	1
24	ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clinical and Translational Oncology, 2019, 21, 1763-1770.	2.4	2
25	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. Leukemia Research, 2019, 85, 106217.	0.8	5
26	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	2.8	44
27	Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. European Journal of Cancer, 2019, 114, 36-46.	2.8	12
28	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. Cancer Research, 2019, 79, 2978-2991.	0.9	13
29	Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. Clinical and Translational Oncology, 2019, 21, 1687-1698.	2.4	4
30	Access to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis. JNCI Cancer Spectrum, 2019, 3, pkz057.	2.9	23
31	The challenge of defining "ultraâ€highâ€risk―neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	. 1.5	43
32	Longâ€ŧerm analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial. Pediatric Blood and Cancer, 2019, 66, e27565.	1.5	7
33	Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trialâ€"A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial Journal of Clinical Oncology, 2019, 37,	1.6	3
34	Old drugs still work! Oral etoposide in a relapsed medulloblastoma. Child's Nervous System, 2019, 35, 865-869.	1.1	3
35	An active drug for TRK-positive paediatric solid tumours. Lancet Oncology, The, 2018, 19, 594-595.	10.7	2
36	Outcome of children and adolescents with central nervous system tumors in phase I trials. Journal of Neuro-Oncology, 2018, 137, 83-92.	2.9	2

#	Article	IF	CITATIONS
37	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. Journal of Neuro-Oncology, 2018, 137, 205-213.	2.9	8
38	Tumor predisposition syndromes: The challenge of de novo mutations. Pediatric Blood and Cancer, 2018, 65, e26882.	1.5	2
39	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	2.8	22
40	Glioblastoma, 47XXY/45,X mosaicism, and hyperpigmented skin lesions. Pediatric Blood and Cancer, 2018, 65, e27299.	1.5	0
41	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	1.5	53
42	Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. European Radiology, 2017, 27, 345-353.	4.5	40
43	Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective. Nature Reviews Clinical Oncology, 2017, 14, 497-507.	27.6	61
44	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	5.0	28
45	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. European Journal of Cancer, 2017, 86, 275-284.	2.8	4
46	Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. Cancer Medicine, 2017, 6, 2606-2624.	2.8	42
47	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De PediatrÃa (English Edition), 2017, 87, 155-163.	0.2	0
48	Outcome of children with relapsed or refractory neuroblastoma: A metaâ€analysis of ITCC/SIOPEN European phase II clinical trials. Pediatric Blood and Cancer, 2017, 64, 25-31.	1.5	61
49	Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. Pediatric Blood and Cancer, 2017, 64, 279-283.	1.5	2
50	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	1.8	16
51	EPT-07PARTICIPATION OF CHILDREN AND ADOLESCENTS WITH CENTRAL NERVOUS SYSTEM TUMOURS IN PHASE I TRIALS WITHIN THE ITCC EUROPEAN CONSORTIUM. Neuro-Oncology, 2016, 18, iii25.2-iii25.	1.2	1
52	The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children. Journal of Clinical Oncology, 2016, 34, 2196-2197.	1.6	7
53	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2016, 129, 109-121.	2.9	30
54	Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents. Anales De PediatrÃa (English Edition), 2016, 85, 274.e1-274.e8.	0.2	1

#	Article	IF	CITATIONS
55	The development of targeted new agents to improve the outcome for children with leukemia. Expert Opinion on Drug Discovery, 2016, 11, 1111-1122.	5.0	7
56	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. European Journal of Cancer, 2016, 67, 130-140.	2.8	17
57	Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. British Journal of Cancer, 2016, 115, 1048-1057.	6.4	62
58	Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. Pediatric Blood and Cancer, 2016, 63, 1400-1406.	1.5	6
59	Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Letters, 2016, 371, 161-170.	7.2	61
60	Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology, 2016, 10, 538-552.	4.6	18
61	Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clinical and Translational Oncology, 2016, 18, 981-987.	2.4	18
62	Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. Journal of Neuro-Oncology, 2016, 126, 81-90.	2.9	68
63	Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology, 2016, 18, 708-713.	2.4	4
64	Phase 1/2 study of weekly <i>nab</i> -paclitaxel (<i>nab</i> -P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK) Journal of Clinical Oncology, 2016, 34, 10551-10551.	1.6	4
65	Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e150-e153.	0.6	12
66	Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. European Journal of Cancer, 2015, 51, 218-224.	2.8	80
67	Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. European Radiology, 2015, 25, 2641-2650.	4.5	22
68	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. Clinical Cancer Research, 2015, 21, 267-273.	7.0	43
69	Targeted approaches to childhood cancer: progress in drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 483-495.	5.0	3
70	Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?. Expert Review of Clinical Pharmacology, 2015, 8, 665-667.	3.1	0
71	Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results Journal of Clinical Oncology, 2015, 33, 10005-10005.	1.6	23
72	Analysis of prognostic factors of clinical outcome in children and adolescents enrolled in phase I trials: a multicentre European collaborative study Journal of Clinical Oncology, 2015, 33, 10049-10049.	1.6	1

#	Article	IF	CITATIONS
73	A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial Journal of Clinical Oncology, 2015, 33, TPS10082-TPS10082.	1.6	6
74	MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets, 2014, 15, 114-123.	2.1	40
75	Toxicity and Outcome of Children and Adolescents Participating in Phase I/II Trials of Novel Anticancer Drugs. Journal of Pediatric Hematology/Oncology, 2014, 36, 218-223.	0.6	25
76	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41
77	At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. British Medical Bulletin, 2013, 108, 173-188.	6.9	13
78	How can attrition rates be reduced in cancer drug discovery?. Expert Opinion on Drug Discovery, 2013, 8, 363-368.	5.0	97
79	Longâ€term followâ€up of children with highâ€risk neuroblastoma: The ENSG5 trial experience. Pediatric Blood and Cancer, 2013, 60, 1135-1140.	1.5	37
80	Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. Journal of Neuro-Oncology, 2013, 111, 169-176.	2.9	18
81	ALK-targeted therapy for poor-prognosis childhood cancers. Lancet Oncology, The, 2013, 14, 439-440.	10.7	5
82	About the Benefits of Immunotherapy for High-Risk Neuroblastoma. Journal of Clinical Oncology, 2013, 31, 649-650.	1.6	2
83	Institutional Experience With Clofarabine and Cytarabine in Relapsed Pediatric Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology, 2012, 34, e17-e21.	0.6	4
84	Is there a role for high dose chemotherapy with hematopoietic stem cell rescue in patients with relapsed supratentorial PNET?. Journal of Neuro-Oncology, 2012, 106, 441-447.	2.9	5
85	Evaluation of chimerism by quantitative PCR analysis of DNA polymorphism after allogeneic hematopoietic stem cell transplantation in a pediatric population with malignancies. Pediatric Transplantation, 2011, 15, 81-87.	1.0	0
86	Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. Journal of Neuro-Oncology, 2011, 105, 135-147.	2.9	30
87	Preclinical drug development for childhood cancer. Expert Opinion on Drug Discovery, 2011, 6, 49-64.	5.0	8
88	Utility of Cerebrospinal Fluid Cytology in Newly Diagnosed Childhood Ependymoma. Journal of Pediatric Hematology/Oncology, 2010, 32, 515-518.	0.6	10
89	Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Child's Nervous System, 2010, 26, 905-911.	1.1	69
90	Solid ovarian tumours in childhood: a 35-year review in a single institution. Clinical and Translational Oncology, 2010, 12, 287-291.	2.4	29

#	Article	IF	CITATIONS
91	Retained intravascular fragments after removal of indwelling central venous catheters: a single institution experience. Journal of Pediatric Surgery, 2010, 45, 1491-1495.	1.6	14
92	Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. European Journal of Cancer, 2010, 46, 2253-2259.	2.8	86
93	Outcome of teenagers and young adults with ependymoma: The Royal Marsden experience. Child's Nervous System, 2009, 25, 1047-1052.	1.1	4
94	Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution. Clinical and Translational Oncology, 2009, 11, 318-321.	2.4	3
95	Ependymoma: An Update. Journal of Child Neurology, 2009, 24, 1431-1438.	1.4	66
96	Abdominal Pain as the First Manifestation of Primary Pancreatic Lymphoma. Journal of Pediatric Hematology/Oncology, 2009, 31, 222-223.	0.6	5
97	Dyspnea as the first manifestation of primary pancreatic lymphoma. Pediatric Blood and Cancer, 2008, 50, 434-434.	1.5	4
98	Can etoposide infusion during stem cell transplantation produce a febrile reaction mimicking bacterial sepsis?. Bone Marrow Transplantation, 2008, 42, 59-60.	2.4	1
99	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro-Oncology, 2005, 71, 33-38.	2.9	80